Cargando…

Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

BACKGROUND: Checkpoint blockade with ipilimumab provides long-term survival to a significant proportion of patients with metastatic melanoma. New approaches to increase survival and to predict which patients will benefit from treatment are needed. This phase II trial combined ipilimumab with carbopl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jamal, Rahima, Lapointe, Réjean, Cocolakis, Eftihia, Thébault, Paméla, Kazemi, Shirin, Friedmann, Jennifer E., Dionne, Jeanne, Cailhier, Jean-François, Bélanger, Karl, Ayoub, Jean-Pierre, Le, Huy, Lambert, Caroline, El-Hajjar, Jida, van Kempen, Léon C., Spatz, Alan, Miller, Wilson H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696743/ https://www.ncbi.nlm.nih.gov/pubmed/29157311 http://dx.doi.org/10.1186/s40425-017-0290-x

Ejemplares similares

Immune biomarker correlates from a Phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM)
por: Lapointe, Réjean, et al.
Publicado: (2015)

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
por: Revicki, Dennis A, et al.
Publicado: (2012)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)
por: Assouline, Sarit, et al.
Publicado: (2012)

Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC
por: Arriola, Edurne, et al.
Publicado: (2016)

Resistance to Cancer Treatment: The Role of Somatic Genetic Events and the Challenges for Targeted Therapies
por: Batist, Gerald, et al.
Publicado: (2011)

Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation
por: Esfahani, Khashayar, et al.
Publicado: (2019)

Innate immunity activation in the early brain injury period following subarachnoid hemorrhage
por: Gris, Typhaine, et al.
Publicado: (2019)

The cost of unresectable stage III or stage IV melanoma in Italy
por: Maio, Michele, et al.
Publicado: (2012)

Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer
por: Yamada, M, et al.
Publicado: (2002)

Ipilimumab and Cancer Immunotherapy: A New Hope for Advanced Stage Melanoma
por: Mansh, Matthew
Publicado: (2011)

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
por: Gibney, Geoffrey T., et al.
Publicado: (2019)

Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab
por: Ma, Vincent T., et al.
Publicado: (2022)

A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
por: Brohl, Andrew S., et al.
Publicado: (2016)

Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection
por: Fujimura, Taku, et al.
Publicado: (2019)

A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma
por: Drysdale, Erik, et al.
Publicado: (2019)

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
por: Yang, Liu, et al.
Publicado: (2023)

Effects of Ipilimumab on expanded tumor infiltrating lymphocytes in patients with stage IV malignant melanoma
por: Bjørn, Jon, et al.
Publicado: (2013)

Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease
por: Cavalcante, Ludimila, et al.
Publicado: (2015)

Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer
por: Horinouchi, Hidehito, et al.
Publicado: (2015)

Advantages of ypTNM Staging in Post-surgical Prognosis for Initially Unresectable or Stage IV Gastric Cancers
por: Jeong, Gyu-Seong, et al.
Publicado: (2020)

Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment
por: Agbarya, Abed, et al.
Publicado: (2022)

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
por: Weber, Jeffrey S., et al.
Publicado: (2023)

Hypofractionated radiotherapy for elderly breast cancer patients: from early stages disease to local palliation for unresectable disease
por: Nair, Vimoj J., et al.
Publicado: (2020)

A pilot study of Ipilimumab in patients with stage IV melanoma receiving palliative radiation therapy
por: Knox, Susan, et al.
Publicado: (2014)

Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy‐naive advanced melanoma
por: Namikawa, Kenjiro, et al.
Publicado: (2020)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
por: Ye, Zhuo-miao, et al.
Publicado: (2022)

Analysis of Lenvatinib’s Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

Ipilimumab
Publicado: (2012)

A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group.
por: Perren, T. J., et al.
Publicado: (1993)

Real‐world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: A postmarketing surveillance
por: Yamazaki, Naoya, et al.
Publicado: (2020)

Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma
por: Yang, Liu, et al.
Publicado: (2022)

Paradigm Shift in the Treatment of Elderly Patients With Unresectable Stage IV Colorectal Cancer
por: Kim, Nam Kyu
Publicado: (2014)

The Role of Surgery for Asymptomatic Primary Tumors in Unresectable Stage IV Colorectal Cancer
por: Kim, Young Wan, et al.
Publicado: (2013)

Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy
por: Blankenstein, Stephanie A., et al.
Publicado: (2020)

Targeted therapies for unresectable stage III non-small cell lung cancer
por: Remon, Jordi, et al.
Publicado: (2021)

Topical imiquimod and cryotherapy in combination with systemic immunotherapy in unresectable stage IIIC melanoma
por: Yeh, Jennifer E., et al.
Publicado: (2022)

Distinct Tryptophan Catabolism and Th17/Treg Balance in HIV Progressors and Elite Controllers
por: Jenabian, Mohammad-Ali, et al.
Publicado: (2013)

Correction: Distinct Tryptophan Catabolism and Th17/Treg Balance in HIV Progressors and Elite Controllers
por: Jenabian, Mohammad-Ali, et al.
Publicado: (2014)

Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma
por: Yamazaki, N., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_t1rcq6gimvgd9qhi9r5frd7j7r